P. Ney

发表

Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP‐sensitive potassium channels

C. Thiemermann, J. Vane, J. Piper, 1995, British journal of pharmacology.

Protection of the ischemic myocardium from reperfusion injury by prostaglandin E1 inhibition of ischemia-induced neutrophil activation

C. Thiemermann, K. Schrör, P. Ney, 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.

Prostaglandin E1 activates the large-conductance KCa channel in human corporal smooth muscle cells

S. Lee, H-Z Wang, W. Zhao, 1999, International Journal of Impotence Research.

Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.

K. Schrör, M. Braun, P. Ney, 1991, Eicosanoids.

Rationale for the combination of PGE(1) and S-nitroso-glutathione to induce relaxation of human penile smooth muscle.

P. Cuevas, A. Martín‐Morales, J. Angulo, 2000, The Journal of pharmacology and experimental therapeutics.

Regulation of human penile smooth muscle tone byprostanoid receptors

P. Cuevas, J. Angulo, Argentina Fernández, 2002, British journal of pharmacology.

The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1.

C. Thiemermann, J. Vane, P. Akarasereenont, 1995, Agents and actions. Supplements.

E‐Type prostaglandins but not iloprost inhibit platelet activating factor‐induced generation of leukotriene B4 by human polymorphonuclear leukocytes

K. Schrör, P. Ney, 1989, British journal of pharmacology.

Thienopyrimidines as β3-adrenoceptor agonists: hit-to-lead optimization.

R. Baumgartner, P. Klahn, J. Schachtner, 2010, Bioorganic & medicinal chemistry letters.

Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2

K. Schrör, P. Ney, G. Hecker, 1990, Naunyn-Schmiedeberg's Archives of Pharmacology.

13,14-dihydro-PGE1 (PGE0) but not 15-keto-PGE1 is a Potent Inhibitor of Human Platelet and Neutrophil Activation

K. Schrör, M. Braun, P. Ney, 1991 .

Cyclic GMP mediates SIN-1-induced inhibition of human polymorphonuclear leukocytes.

K. Schrör, H. Schröder, P. Ney, 1990, European journal of pharmacology.

The thromboxane receptor antagonist, daltroban, protects the myocardium from ischaemic injury resulting in suppression of leukocytosis.

C. Thiemermann, K. Schrör, P. Ney, 1988, European journal of pharmacology.

PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils.

K. Schrör, P. Ney, 1991, Eicosanoids.

An aryloxypropanolamine hβ3-adrenoceptor agonist as bladder smooth muscle relaxant.

D. Behr-Roussel, D. Gorny, F. Giuliano, 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

A „Closed-Loop-Stripping“ Technique as a Versatile Tool for Metabolic Studies of Volatiles

W. Boland, L. Jaenicke, P. Ney, 1984 .

Biosynthesis of 1-alkenes in higher plants. A model study with the composite Carthamus tinctorius L.

P. Ney, W. Boland, 1987, European journal of biochemistry.

Vasodilator effects of PGE1 in the coronary and systemic circulation of the rat are mediated by ATP-sensitive potassium (K+) channels.

M. Feelisch, P. Ney, 1995, Agents and actions. Supplements.

Securing the Future of Biotechnology: A Study of Emerging Bio-Cyber Security Threats to DNA-Information Systems

Peter Martin Ney, P. Ney, 2019 .

One-Pot Conversion of Carboxylic-Acid Esters and Lactones to Olefinic Compounds

W. Boland, L. Jaenicke, P. Ney, 1980 .

Potent inhibition of PAF-stimulated human platelets and polymorphonuclear leukocytes by the PGE1 analog OP-1206.

K. Schrör, P. Ney, G. Hecker, 1987, Progress in clinical and biological research.

Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo

R. Pandita, D. Newgreen, K. Andersson, 2008, BJU international.

Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.

H Friehe, P Ney, P. Ney, 1997, Arzneimittel-Forschung.

Nitrovasodilator-induced inhibition of LTB4 release from human PMN may be mediated by cyclic GMP.

K. Schrör, H. Schröder, P. Ney, 1990, Eicosanoids.

A vHTS approach for the identification of beta-adrenoceptor ligands.

R. Baumgartner, J. Schachtner, S. Tasler, 2010, Bioorganic & medicinal chemistry letters.